Updated Guidelines for Managing HIV/HCV Co-Infection

Size: px
Start display at page:

Download "Updated Guidelines for Managing HIV/HCV Co-Infection"

Transcription

1 Updated Guidelines for Managing HIV/HCV Co-Infection John J Faragon, PharmD, BCPS, AAHIV-P Regional Pharmacy Director, NY/NJ AIDS Education and Training Center Pharmacist, HIV Medicine, Albany Medical Center

2 Released 1/29/14!

3 Abbreviations BOC boceprevir DAA direct acting antiviral IFN interferon PEG pegylated interferon RBV WB ribavirin, weight based dosing RGT response guided therapy SMV simeprevir SOF sofosbuvir TVR telaprevir

4 IFN Ineligible Definitions Intolerance to IFN Autoimmune hepatitis and other autoimmune disorders Hypersensitivity to PEG or any of its components Decompensated hepatic disease History of depression, or clinical features consistent with depression A baseline neutrophil count below 1500/μL, a baseline platelet count below 90,000/μL or baseline hemoglobin below 10 g/dl A history of preexisting cardiac disease

5 Standard Dosing Sofosbuvir 400mg once daily Simeprevir 150mg once daily Peg Interferon 180mcg once weekly Ribavirin weight based dosing <75kg 1000mg daily in divided doses 75 kg 1200mg daily in divided doses

6 Drug Interactions Considerations Sofosbuvir Substrate for P-glycoprotein and breast cancer resistance protein Intracellular metabolism mediated by hydrolase and nucleotide phosphorylation pathways Minimal drug interactions expected Simeprevir Mild inhibitor of CYP1A2 activity and intestinal CYP3A4 Does not affect hepatic CYP3A4 activity Inhibits OATP1B1/3 and P-glycoprotein Multiple drug interactions expected

7 Sofosbuvir and HIV Medications (1 of 2) Concurrent Medication Recommendation HIV Protease Inhibitors All HIV PIs, with or without Concurrent use at standard doses acceptable. Interactions not ritonavir, except tipranavir expected based upon metabolism of sofosbuvir. Tipranavir (Aptivus ) Co-administration not recommended HIV Non Nucleoside Reverse Transcriptase Inhibitors All NNRTIs Concurrent use at standard doses acceptable.

8 Sofosbuvir and HIV Medications (2 of 2) Concurrent Medication Recommendation HIV Integrase Strand Transfer Inhibitors Dolutegravir (Tivicay ) Concurrent use at standard doses acceptable. Interactions not expected based upon metabolism of sofosbuvir. Elvitegravir (contained in Stribild ) Concurrent use at standard doses acceptable. Interactions not expected based upon metabolism of sofosbuvir. Raltegravir (Isentress ) Concurrent use at standard doses acceptable. HIV Entry Inhibitors Maraviroc (Selzentry ) Concurrent use at standard doses acceptable. Interactions not expected based upon metabolism of sofosbuvir. HIV Nucleoside/Nucleotide Reverse Transcriptase Inhibitors All NRTIs Concurrent use at standard doses acceptable. Interactions not expected based upon metabolism of sofosbuvir.

9 Simeprevir and HIV Medications (1 of 2) Concurrent Medication HIV Protease Inhibitors Recommendation All HIV PIs Significant increases or decreases in simeprevir levels expected when used with any HIV protease inhibitor, when used with or without ritonavir. Co-administration not recommended HIV Non Nucleoside Reverse Transcriptase Inhibitors Efavirenz (Sustiva ), Etravirine (Intelence ), Nevirapine (Viramune ) Significant reductions in simeprevir levels and reduced simeprevir efficacy due to CYP3A4 induction. Coadministration not recommended. Rilpivirine (Edurant ) Concurrent use at standard doses acceptable.

10 Simeprevir and HIV Medications (2 of 2) Concurrent Medication Recommendation HIV Integrase Strand Transfer Inhibitors Dolutegravir (Tivicay ) Concurrent use at standard doses acceptable. Interactions not expected based upon metabolism of simeprevir. Elvitegravir (contained in Stribild ) Significant increase in simeprevir levels expected when used with a cobicistat containing regimen. Co-administration not recommended. Raltegravir (Isentress ) Concurrent use at standard doses acceptable. HIV Entry Inhibitors Maraviroc (Selzentry ) Concurrent use at standard doses acceptable. Interactions not expected based upon metabolism of simeprevir. HIV Nucleoside/Nucelotide Reverse Transcriptase Inhibitors All NRTIs Concurrent use at standard doses acceptable. Interactions not expected based upon metabolism of simeprevir.

11 HIV/HCV Co-Infection, GT1 Preferred Treatment-naïve, prior PEG/RBV relapsers, IFN eligible: SOF + PEG/RBV(WB) x 12 weeks IFN ineligible: SOF + RBV(WB) x 24 weeks SOF + SMV ± RBV(WB) x 12 weeks Treatment experienced, prior PEG/RBV nonresponders, regardless of IFN eligibility: SOF + SMV ± RBV(WB) x 12 weeks Alternative Treatment-naïve, prior PEG/RBV relapsers, IFN eligible: SMV x 12 weeks + PEG/RBV(WB) x 24 weeks IFN ineligible: None Treatment experienced, prior PEG/RBV nonresponders IFN eligible: SOF + PEG/RBV(WB) x 12 Weeks IFN ineligible: SOF + RBV(WB) x 24 Weeks Not Recommended: TVR + PEG/RBV x 24 or 48 weeks (RGT), BOC + PEG/RBV x 28 or 48 weeks (RGT) PEG/RBV x 48 weeks, SMV x 12 weeks + PEG/RBV x 48 wks

12 HIV/HCV Co-Infection, GT2 Preferred All patients, regardless of treatment history: SOF + RBV(WB) x 12 weeks Alternative Treatment naive and prior PEG/RBV relapsers: None Treatment experienced, prior PEG/RBV Nonresponders: IFN eligible: SOF + PEG/RBV(WB) X 12 Weeks IFN ineligible: None Not Recommended: PEG/RBV x weeks, or any regimen with TVR, BOC, or SMV

13 HIV/HCV Co-Infection, GT3 Preferred All patients, regardless of treatment history: SOF + RBV(WB) x 24 weeks Alternative Treatment naïve, PEG/RBV relapsers: None Treatment experienced, prior PEG/RBV Nonresponders: IFN eligible: SOF + PEG/RBV(WB) X 12 weeks IFN ineligible: None Not Recommended: PEG/RBV x weeks, Any regimen with TVR, BOC, or SMV

14 HIV/HCV Coinfection, GT4 Preferred All patients, regardless of treatment history: Alternative None IFN eligible: SOF + PEG/RBV(WB) x 12 weeks IFN ineligible: SOF + RBV(WB) x 24 weeks Not Recommended: PEG/RBV x 48 weeks, any regimen with TVR or BOC

15 HIV/HCV Coinfection, GT 5,6 Preferred All patients, regardless of treatment history: SOF + PEG/RBV(WB) x 12 weeks Alternative None Not Recommended: PEG/RBV x 48 weeks, any regimen with TVR, BOC, or SMV

16 HIV/HCV NOT Recommended Not Recommended for treatment-naïve or treatment-experienced patients: PEG/RBV with or without telaprevir or boceprevir for 24 to 48 weeks Monotherapy with PEG, RBV, or a DAA

17 Other Drug Interactions with Sofosbuvir Medication and or Class Anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antimycobacterials rifampin, rifabutin, rifapentin Rationale for Avoiding with Sofosbuvir Co-administration with these medications is likely to reduce concentrations of sofosbuvir leading to reduced sofosbuvir efficacy. Co-administration not recommended. Co-administration with these medications is likely to reduce concentrations of sofosbuvir leading to reduced sofosbuvir efficacy due to intestinal P-glycoprotein (P-gp) induction from rifampin. Herbal products St. John s Wort Co-administration with these medications is likely to reduce concentrations of sofosbuvir leading to reduced sofosbuvir efficacy due to intestinal P-glycoprotein (P-gp) induction associated with St. John s Wort.

18 Other Drug Interactions with Simeprevir (1 of 2) Medication and or Class Anticonvulsants - carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antibiotics clarithromycin, erythromycin, telithromycin Antifungals fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole Antimycobacterials rifampin, rifabutin, rifapentine Rationale for Avoiding with Simeprevir Co-administration with these medications is likely to reduce concentrations of simeprevir and lead to reduced simeprevir efficacy. Co-administration not recommended. Co-administration with these medications is likely to increase concentrations of either simeprevir or the antibiotic due to CYP3A4 and P-glycoprotein (P-gp) inhibition. Co-administration not recommended. Co-administration with these medications is likely to increase concentrations of simeprevir due to CYP3A4 inhibition from the antifungals. Co-administration not recommended. Co-administration with these medications is likely to reduce concentrations of simeprevir and lead to reduced simeprevir efficacy. Co-administration not recommended.

19 Other Drug Interactions with Simeprevir (2 of 2) Medication and or Class Corticosteroids dexamethasone Rationale for Avoiding with Simeprevir Co-administration with dexamethasone is likely to decrease concentrations of simeprevir and lead to reduced simeprevir efficacy. Co-administration not recommended. Propulsive cisapride Co-administration with cisapride may result in increased concentrations of cisapride leading to potential cardiac arrhythmias. Herbal products Milk Thistle, St. John s Wort Co-administration with milk thistle is likely to increase concentrations of simeprevir. Co-administration not recommended. Co-administration with St. John s Wort is likely to reduce concentrations of simeprevir leading to reduced simeprevir efficacy, due to intestinal P-glycoprotein (P-gp) induction associated with St. John s Wort.

20 Select HIV/HCV Resources

21

22 CLICK HERE

23 CLICK HERE

24 NY/NJ AETC

25 NY/NJ AETC

HIV and HCV Drug Interactions Cased Based Discussion. John J. Faragon, PharmD, BCPS, AAHIV-P. Brief background on HCV and HIV Coinfection

HIV and HCV Drug Interactions Cased Based Discussion. John J. Faragon, PharmD, BCPS, AAHIV-P. Brief background on HCV and HIV Coinfection HIV and HCV Drug Interactions Cased Based Discussion John J. Faragon, PharmD, BCPS, AAHIV-P Roadmap Brief background on HCV and HIV Coinfection Revised AASLD Guidelines Case evaluating drug interactions

More information

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir

More information

Disclosure Statement. Hepatitis C. HIV/HCV Co-infection. Major Hepatitis Viruses. Hepatitis: definition. Hepatitis C and HIV/HCV Coinfection 1

Disclosure Statement. Hepatitis C. HIV/HCV Co-infection. Major Hepatitis Viruses. Hepatitis: definition. Hepatitis C and HIV/HCV Coinfection 1 Disclosure Statement Hepatitis C and HIV/HCV Co-infection No conflicts of interest exist between the speaker and any entity No endorsements of any products based on bias exist with the speaker Dell Robertson,

More information

ANTIRETROVIRAL TREATMENTS (Part 1of

ANTIRETROVIRAL TREATMENTS (Part 1of CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after

More information

Odefsey. (emtricitabine, rilpivirine, tenofovir alafenamide) New Product Slideshow

Odefsey. (emtricitabine, rilpivirine, tenofovir alafenamide) New Product Slideshow Odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) New Product Slideshow Introduction Brand name: Odefsey Generic name: Emtricitabine, rilpivirine, tenofovir alafenamide (TAF) Pharmacological

More information

Summary Tables NEW DRUGS IN HCV. LUIS S. MARSANO, MD January 2015

Summary Tables NEW DRUGS IN HCV. LUIS S. MARSANO, MD January 2015 Summary Tables NEW DRUGS IN HCV LUIS S. MARSANO, MD January 2015 Simeprivir (OLYSIO) Sofosbuvir (SOVALDI) Drug Group NS3/4A Protease inhibitor NS5B polymerase inhibitor Nucleotide analog Genotypes affected

More information

State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT

State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT HCV Phone: 1-888-445-0497 www.mainecarepdl.org Fax: 1-888-879-6938 Member ID #: Patient

More information

State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT

State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT HCV Phone: 1-888-445-0497 www.mainecarepdl.org Fax: 1-888-879-6938 Member ID #: Patient

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked

More information

HIV Drugs and the HIV Lifecycle

HIV Drugs and the HIV Lifecycle HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Hepatitis C First Generation Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred

More information

REQUEST FOR PRIOR AUTHORIZATION Hepatitis C Treatments

REQUEST FOR PRIOR AUTHORIZATION Hepatitis C Treatments Fax completed form to: 866-940-7328 Prior Authorization Phone Number: 800-310-6826 IA Medicaid Member ID # Patient name Date of Birth Patient address Patient phone Provider NPI Prescriber name Phone Prescriber

More information

INFECTIOUS DISEASE AGENTS: HEPATITIS C - DIRECT - ACTING ANTIVIRAL

INFECTIOUS DISEASE AGENTS: HEPATITIS C - DIRECT - ACTING ANTIVIRAL Ohio Department of Medicaid Prior Authorization Form Unified PDL HEPATITIS C TREATMENT Member ID# Patient Name: DOB: Patient Address: Provider DEA: Provider NPI: Provider Name: Phone: Provider Address:

More information

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients 5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked

More information

A Practical Approach to HIV/HCV Co-infection

A Practical Approach to HIV/HCV Co-infection A Practical Approach to HIV/HCV Co-infection Focus on Drug-Drug Interactions Amy Hirsch Shumaker, PharmD, BCPS HIV/Hepatitis C Clinical Pharmacy Specialist Louis Stokes Cleveland VA Medical Center Andrea

More information

HIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16

HIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16 HIV/HCV Coinfection: Why It Matters and What To Do About It Cody A. Chastain, MD 10/26/16 Disclosures I have no relevant financial disclosures. Objectives At the end of this lecture, the learner will be

More information

Update on Real-World Experience With HARVONI

Update on Real-World Experience With HARVONI Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were

More information

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/

More information

Update on Real-World Experience With HARVONI

Update on Real-World Experience With HARVONI Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data

More information

Sofosbuvir (Sovaldi) Drug Summary. Class and Mechanism. Table of Contents

Sofosbuvir (Sovaldi) Drug Summary. Class and Mechanism. Table of Contents Hepatitis C Online PDF created July 12, 2018, 1:44 pm Sofosbuvir (Sovaldi) Table of Contents Sofosbuvir Sovaldi Editor's Summary Drug Summary Class and Mechanism Manufacturer for United States Cost and

More information

Fluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids

Fluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids Supportive therapy Summary of interactions Table 1. Summary of potential interactions between antiretroviral agents and supportive therapy Interactions with enzyme inhibitors (protease inhibitors and elvitegravir/cobicistat)

More information

HIV Management Update 2015

HIV Management Update 2015 9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe

More information

6/2/2015. Interactive Case-Based Presentations and Audience Discussion

6/2/2015. Interactive Case-Based Presentations and Audience Discussion Interactive Case-Based Presentations and Audience Discussion Charles W. Flexner, MD Professor of Medicine, Pharmacology, and International Health The Johns Hopkins University Baltimore, Maryland Formatted:05-05-2015

More information

California Department of Health Care Services Utilization and Treatment Policy for Simeprevir and Sofosbuvir in the Management of Hepatitis C

California Department of Health Care Services Utilization and Treatment Policy for Simeprevir and Sofosbuvir in the Management of Hepatitis C Introduction California Department of Health Care Services Utilization and Treatment Policy for Simeprevir and Sofosbuvir in the Management of Hepatitis C This policy was developed by the California Department

More information

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core

More information

HCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES

HCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University

More information

Hepatits C Criteria Direct Acting Antiviral Medications

Hepatits C Criteria Direct Acting Antiviral Medications Hepatits C Criteria Direct Acting Antiviral Medications Harvoni-Formulary PA required 1. Is the patient being treated for a funded condition by the Oregon Health Plan? 2. Does the member have a diagnosis

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked

More information

Simeprevir (Olysio) Drug Summary. Class and Mechanism. Table of Contents

Simeprevir (Olysio) Drug Summary. Class and Mechanism. Table of Contents Hepatitis C Online PDF created September 18, 2018, 1:01 pm Simeprevir (Olysio) Table of Contents Simeprevir Olysio Editor's Summary Drug Summary Class and Mechanism Manufacturer for United States Cost

More information

Hepatitis B virus (HBV) reactivation has been reported, in some cases resulting in fulminant hepatitis, hepatic failure, and death. (5.

Hepatitis B virus (HBV) reactivation has been reported, in some cases resulting in fulminant hepatitis, hepatic failure, and death. (5. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OLYSIO safely and effectively. See full prescribing information for OLYSIO. OLYSIO (simeprevir) capsules,

More information

Simeprevir (Galexos)

Simeprevir (Galexos) FACTSHEET Simeprevir (Galexos) Summary Simeprevir is a medication used to treat Hep C. It is used in combination with other medications to cure people of the Hep C virus. It is approved in Canada for people

More information

Antiretroviral Dosing in Renal Impairment

Antiretroviral Dosing in Renal Impairment Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis

More information

Sovaldi + Olysio + ribavirin Harvoni + ribavirin. Sovaldi + ribavirin Viekira Pak

Sovaldi + Olysio + ribavirin Harvoni + ribavirin. Sovaldi + ribavirin Viekira Pak Hepatitis Prior Authorization Request CVS Caremark administers the specialty pharmacy benefit plan for the patient identified. This patient s benefit plan requires prior authorization for certain medications

More information

Direct Acting Antivirals for the Treatment of Hepatitis C Infection

Direct Acting Antivirals for the Treatment of Hepatitis C Infection Hepatitis C Core Curriculum, Module 2 Direct Acting Antivirals for the Treatment of Hepatitis C Infection Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Objectives Discuss the evolution of hepatitis C treatment

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked

More information

Juluca (dolutegravir, rilpivirine) NEW PRODUCT SLIDESHOW

Juluca (dolutegravir, rilpivirine) NEW PRODUCT SLIDESHOW Juluca (dolutegravir, rilpivirine) NEW PRODUCT SLIDESHOW Introduction Brand name: Juluca Generic name: Dolutegravir, rilpivirine Pharmacological class: HIV-1 integrase strand transfer inhibitor (INSTI)

More information

Hepatitis C (Direct Acting Antiviral Medications for Treatment of Hepatitis C) QUEST Integration Formulary

Hepatitis C (Direct Acting Antiviral Medications for Treatment of Hepatitis C) QUEST Integration Formulary Hepatitis C (Direct Acting Antiviral Medications for Treatment of Hepatitis C) QUEST Integration Formulary Policy Number: Original Effective Date: MM.04.036 06/01/2015 Lines of Business: Current Effective

More information

Considerations for the management of Hepatitis C in patients with HIV co-infection

Considerations for the management of Hepatitis C in patients with HIV co-infection Considerations for the management of Hepatitis C in patients with HIV co-infection Marcella Honkonen, PharmD, BCPS Sunday, February 22, 2012 at 10:15 AM AzPA Southwest Clinical Conference JW Marriott,

More information

Treatments of Genotype 2, 3,and 4: Now and in the future

Treatments of Genotype 2, 3,and 4: Now and in the future Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve

More information

AmeriHealth Caritas Iowa Request for Prior Authorization Hepatitis C Treatments

AmeriHealth Caritas Iowa Request for Prior Authorization Hepatitis C Treatments Form applies to IA Health Link and hawk-i plans. Please print accuracy is important. Fax completed form to 1-855-825-2714. Provider Help Desk: 1-855-328-1612. AmeriHealth Caritas Iowa member ID #: Patient

More information

Pharmacokinetics1, 2, 3, 4 Tmax

Pharmacokinetics1, 2, 3, 4 Tmax Brand Name: Olysio Generic Name: Simeprevir Manufacturer: Janssen Therapeutics Drug Class: NSIII/IVA protease inhibitor Uses Labeled: hepatitis C infection (genotype I) Unlabeled: hepatitis C infection

More information

Harvoni (sofosbuvir/ledipasvir

Harvoni (sofosbuvir/ledipasvir Market DC Override(s) Prior Authorization Quantity Limit (sofosbuvir/ledipasvir) Approval Duration Based on Genotype, Treatment status, Baseline HCV RNA status, Cirrhosis status, Transplant status, or

More information

Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV)

Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Amantadine and Rimantadine Use is limited to Influenza A infection. Very effective in preventing infection if

More information

Global Prevalence of HBV, HCV, HIV

Global Prevalence of HBV, HCV, HIV Treatment of Patients with HCV and HIV Paul Y. Kwo, MD, FACG Professor of Medicine Stanford University email: pkwo@stanford.edu Global Prevalence of HBV, HCV, HIV 24 m Journal of Clinical Virology Page

More information

Update in the Management of Hepatitis C: What Does the Future Hold

Update in the Management of Hepatitis C: What Does the Future Hold Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana

More information

Sovaldi (sofosbuvir)

Sovaldi (sofosbuvir) Market DC Sovaldi (sofosbuvir) Override(s) Prior Authorization Quantity Limit Approval Duration Based on Genotype, Treatment status, Cirrhosis status, or Ribavirin Eligibility status **IN, SC, WA Medicaid

More information

Hepatitis C Genotypes

Hepatitis C Genotypes 9/2/21 OBJECTIVES Project ECHO HCV Collaborative HCV in 21: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College

More information

Hepatitis C: The New World of Treatment

Hepatitis C: The New World of Treatment Hepatitis C: The New World of Treatment Aban 1395, NIOC Hospital Shahin Merat, M.D. Professor of Medicine Digestive Disease Research Institute Tehran University of Medical Sciences 1 Drugs NS5B polymerase

More information

A Practical Guide to Hepatitis C Management

A Practical Guide to Hepatitis C Management A Practical Guide to Hepatitis C Management David C. Wolf, M.D., FACP, FACG, AGAF Medical Director of Liver Transplantation Westchester Medical Center Professor of Clinical Medicine New York Medical College

More information

Package Insert. Virso

Package Insert. Virso Package Insert Virso Product Summary 1. Name of the medicinal product Virso 2. Qualitative and quantitative composition Each film coated tablet contains: Sofosbuvir 400 mg Excipients 3. Pharmaceutical

More information

HIV-HCV coinfection. Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland

HIV-HCV coinfection. Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland HIV-HCV coinfection Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures Principal investigator for research grants Funds paid to Johns Hopkins

More information

Ledipasvir-Sofosbuvir (Harvoni)

Ledipasvir-Sofosbuvir (Harvoni) HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical

More information

treatment passport 1

treatment passport 1 treatment passport 1 Why keep a treatment history? Keeping a short record of your treatment history can help in many ways. It can help you understand your health and treatment. It can help if your doctor

More information

Pharmacologic Considerations of HCV Treatment. Autumn Zuckerman, PharmD, BCPS, AAHIVP

Pharmacologic Considerations of HCV Treatment. Autumn Zuckerman, PharmD, BCPS, AAHIVP Pharmacologic Considerations of HCV Treatment Autumn Zuckerman, PharmD, BCPS, AAHIVP Objectives Review pharmacokinetic properties of currently utilized Hepatitis C medications Review drug interactions

More information

1/16/2019. Goals of HCV Therapy. Objectives. Treating Hepatitis C and HIV Co Infection. Cure Defined as sustained virologic response (SVR)

1/16/2019. Goals of HCV Therapy. Objectives. Treating Hepatitis C and HIV Co Infection. Cure Defined as sustained virologic response (SVR) HCV ECHO WESTERN STATES HCV ECHO WESTERN STATES Treating Hepatitis C and HIV Co Infection Paulina Deming, Pharm D Associate Professor, College of Pharmacy Assistant Director, Viral Hepatitis Programs,

More information

HIV and Hepatitis C: Advances in Treatment

HIV and Hepatitis C: Advances in Treatment NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and Hepatitis C: Advances in Treatment John Scott, MD, MSc Asst Professor University of Washington Presentation prepared & presented by: John Scott, MD,

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HARVARD PILGRIM HEALTH CARE Generic Brand HICL GCN Exception/Other SOFOSBUVIR/VELPATASVIR EPCLUSA TBD CUSTOMER SERVICE REPRESENTATIVE (CSR) If the member lives in Rhode Island or if the prescribing physician

More information

Separate clinical trials for HIV- HCV coinfected patients are NOT a necessity. Patrick Ingiliz, Berlin

Separate clinical trials for HIV- HCV coinfected patients are NOT a necessity. Patrick Ingiliz, Berlin Separate clinical trials for HIV- HCV coinfected patients are NOT a necessity Patrick Ingiliz, Berlin Back in the days when HCV genotype 1 was the problem SVR (%) 100 90 80 70 60 50 40 30 20 10 0 35% PRESCO

More information

Program Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.

Program Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours. Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship

More information

Description of Antivirals for Hepatitis C. LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases

Description of Antivirals for Hepatitis C. LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases Description of Antivirals for Hepatitis C LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases Dwayne-David@cherokee.org Objectives Compare the different classes of direct-acting antiviral

More information

PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline

PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir) PHARMACY PRI AUTHIZATION Hepatitis C Clinical Guideline Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir) Harvoni

More information

WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION

WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Excipient with known effect: Darunavir Alvogen 400 mg: Each tablet contains mg sunset yellow FCF (E110).

SUMMARY OF PRODUCT CHARACTERISTICS. Excipient with known effect: Darunavir Alvogen 400 mg: Each tablet contains mg sunset yellow FCF (E110). SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Darunavir Alvogen 400 mg, filmomhulde tabletten Darunavir Alvogen 800 mg, filmomhulde tabletten 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

More information

Daklinza (Daclatasvir) & Sovaldi (Sofosbuvir) Treatment Agreement

Daklinza (Daclatasvir) & Sovaldi (Sofosbuvir) Treatment Agreement Daklinza (Daclatasvir) & Sovaldi (Sofosbuvir) Treatment Agreement Liver Disease & Hepatitis Program Providers: Brian McMahon, MD; Youssef Barbour, MD; Lisa Townshend-Bulson, FNP-C; Annette Hewitt, FNP-C;

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked

More information

Hepatitis C Medications Prior Authorization Criteria

Hepatitis C Medications Prior Authorization Criteria Hepatitis C Medications Authorization Criteria Epclusa (/velpatasvir), Harvoni (ledipasvir/), Sovaldi (), Daklinza (daclatasvir), Zepatier (elbasvir/grazoprevir), Olysio (simeprevir), Viekira Pak (ombitasvir/paritaprevir/ritonavir;

More information

Hepatitis C Genotype 1 (GT 1) Patients in the United States (US)

Hepatitis C Genotype 1 (GT 1) Patients in the United States (US) Hepatitis C Genotype 1 (GT 1) Patients in the United States (US) INDICATION is indicated with or without ribavirin for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or

More information

Protocol. This trial protocol has been provided by the authors to give readers additional information about their work.

Protocol. This trial protocol has been provided by the authors to give readers additional information about their work. Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir

More information

PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline

PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)

More information

Hepatitis C Emerging Treatment Paradigms

Hepatitis C Emerging Treatment Paradigms Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,

More information

HCV Case Study. Treat Now or Wait for New Therapies

HCV Case Study. Treat Now or Wait for New Therapies HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented

More information

New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret

New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical

More information

1. MEDICINAL PRODUCT FOR COMPASSIONATE USE

1. MEDICINAL PRODUCT FOR COMPASSIONATE USE 21 November 2013 Evaluation of Medicines for Human Use Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring adressed to member states for Daclatasvir

More information

Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need

Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need Infect Dis Ther (2016) 5:299 312 DOI 10.1007/s40121-016-0118-x REVIEW Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need Monique R. Bidell. Milena McLaughlin.

More information

Selected Properties of Daclatasvir

Selected Properties of Daclatasvir Selected Properties of Daclatasvir Other names Manufacturer Pharmacology / Mechanism of Action Activity Resistance Genotypic Daklinza, BMS-790052 Bristol-Myers Squibb Daclatasvir is a highly potent and

More information

Developments in the Treatment of Hepatitis C: A New Era

Developments in the Treatment of Hepatitis C: A New Era Developments in the Treatment of Hepatitis C: A New Era Nancy Love, PharmD, BCPS Memorial Medical Center, Johnstown, PA October 17, 2014 Pharmacist Objectives Summarize the results of clinical trials for

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT PREZISTA 100 mg/ml oral suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of oral suspension contains 100 mg of

More information

HIV, Hepatitis C, and Treatment 3/26/13. What Do HIV Medications Do? George Beatty, MD, MPH

HIV, Hepatitis C, and Treatment 3/26/13. What Do HIV Medications Do? George Beatty, MD, MPH HIV, Hepatitis C, and Treatment 3/26/13 What Do HIV Medications Do? George Beatty, MD, MPH BIOGRAPHY: Dr Beatty is a clinician educator and has been on the faculty since 1998. He served as Director of

More information

Pharmaceutical Care Information Pack

Pharmaceutical Care Information Pack Reproduced with kind permission from NHS Greater Glasgow and Clyde and NHS Tayside Version 1; Date written April 2015 NHS LOTHIAN Community Pharmacy Supply of Medicines for Hepatitis C Pharmaceutical Care

More information

How one pharmacy is bringing specialty drugs to an independent community pharmacy setting

How one pharmacy is bringing specialty drugs to an independent community pharmacy setting , S E Y t a h t it s How one pharmacy is bringing specialty drugs to an independent community pharmacy setting by LeAnn W. O Neill, PharmD; Vanessa K. Hoffman, PharmD, CGP; Barry S. Bryant, RPh; and John

More information

On Target for Hepatitis C Elimination: Direct Acting Antiviral Agents in 2018

On Target for Hepatitis C Elimination: Direct Acting Antiviral Agents in 2018 On Target for Hepatitis C Elimination: Direct Acting Antiviral Agents in 2018 Trana Hussaini, PharmD Pharmacotherapy Specialist in Liver Transplantation, VGH Clinical Assistant Professor, Faculty of Pharmaceutical

More information

Section 6: Treatment of Hepatitis C virus (HCV)

Section 6: Treatment of Hepatitis C virus (HCV) Section 6: Treatment of Hepatitis C virus (HCV) Dr. Niklas Luhmann (Médecins du Monde) Training Hepatitis C and HR for PWUD, 9 th -13 th May 2016, Hanoi, Vietnam Learning objective of the session: understanding

More information

Dr Janice Main Imperial College Healthcare NHS Trust, London

Dr Janice Main Imperial College Healthcare NHS Trust, London BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE

More information

Concomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications.

Concomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications. Avifanz Tablet Description Avifanz is the brand name for Efavirenz. Efavirenz, a synthetic antiretroviral agent, is a non-nucleoside reverse transcriptase inhibitor. While Efavirenz is pharmacologically

More information

Daclatasvir (Daklinza)

Daclatasvir (Daklinza) FACTSHEET Daclatasvir (Daklinza) Summary Daclatasvir (Daklinza) is a medication used to treat hepatitis C. It is taken with sofosbuvir (Sovaldi) and sometimes ribavirin. This combination is approved in

More information

PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS

PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS 8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI

More information

HEPATITIS C. Mitchell L. Shiffman, MD, FACG Director. Liver Institute of Virginia. Richmond and Newport News, VA

HEPATITIS C. Mitchell L. Shiffman, MD, FACG Director. Liver Institute of Virginia. Richmond and Newport News, VA NEW TREATMENTS FOR HEPATITIS C Mitchell L. Shiffman, MD, FACG Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research

More information

Pharmacy Medical Necessity Guidelines: Hepatitis C Virus

Pharmacy Medical Necessity Guidelines: Hepatitis C Virus Pharmacy Medical Necessity Guidelines: Hepatitis C Virus Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX)

More information

Evolution of Therapy in HCV

Evolution of Therapy in HCV Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR

More information

Antiviral treatment in Unique Populations

Antiviral treatment in Unique Populations Antiviral treatment in Unique Populations Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Unique HCV Populations HIV/HCV co-infected

More information

CURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA

CURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and

More information

Sofosbuvir and Velpatasvir. (Systemic) Cautions. Uses. Dosage and Administration

Sofosbuvir and Velpatasvir. (Systemic) Cautions. Uses. Dosage and Administration Sofosbuvir and Velpatasvir (Systemic) HCV antiviral; fixed combination containing sofosbuvir (nucleotide analog HCV NS5B polymerase inhibitor) and (HCV NS5A replication complex inhibitor [NS5A inhibitor]).

More information

Topic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015

Topic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014

More information

Descovy FACTSHEET. Summary. What is Descovy? How does Descovy work?

Descovy FACTSHEET. Summary. What is Descovy? How does Descovy work? FACTSHEET Descovy Summary Descovy is the name given to a pill containing the following two anti- HIV drugs: TAF (tenofovir alafenamide) and FTC (emtricitabine). Descovy comes in two, colour-coded strengths

More information

Tough Cases in HIV/HCV Coinfection

Tough Cases in HIV/HCV Coinfection NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio

More information

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals Antiretroviral Medications: What you need to know Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Associate Professor, Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University

More information